In SELECT, the benefit of semaglutide on MACE risk reduction occurred early, prior to full titration to the target maintenance dose of 2.4 mg for weight loss, 20 and only 77% of patients were taking this dose by study Year 2
Call us today to set up your free consultation.
Setting realistic, incremental goals helps prevent frustration and disappointment
Drug expiry debate: the myth and the reality - African Health Science Assessment report: Ozempic - European Medicines Agency Exploring beyond numeric weight loss: The metabolic effects of semaglutide - Clinical nutrition ESPEN Expiration Dates - FDA Insulin Storage: A Critical Reappraisal - Journal of Diabetes Science & Technology Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages - Clinical Diabetes, American Diabetes Association APIC position paper: Safe injection, infusion, and medication vial practices in health care - American Journal of Infection Control
Severe insulin resistance associated with conditions like non-alcoholic fatty liver disease (NAFLD) or metabolic syndrome may require higher semaglutide doses or combination therapy to overcome
The weight loss from semaglutide comes primarily from reduced appetite and altered food preferences through central nervous system pathways, not from feeling too nauseous to eat
